Senzime AB (publ) (STO:SEZI)
Sweden · Delayed Price · Currency is SEK 3.280
-0.020 (-0.61%)
Sep 4, 2026, 5:29 PM CET
Senzime AB Revenue
Senzime AB had revenue of 24.67M SEK in the quarter ending June 30, 2026, a decrease of -3.99%. This brings the company's revenue in the last twelve months to 102.73M, up 27.40% year-over-year. In the year 2025, Senzime AB had annual revenue of 104.02M with 77.89% growth.
Revenue (ttm)
102.73M
Revenue Growth
+27.40%
P/S Ratio
5.02
Revenue / Employee
1.74M
Employees
59
Market Cap
515.67M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 104.02M | 45.55M | 77.89% |
| Dec 31, 2024 | 58.48M | 22.72M | 63.55% |
| Dec 31, 2023 | 35.75M | 21.72M | 154.77% |
| Dec 31, 2022 | 14.03M | 3.05M | 27.81% |
| Dec 31, 2021 | 10.98M | 1.64M | 17.60% |
| Dec 31, 2020 | 9.34M | 2.63M | 39.13% |
| Dec 31, 2019 | 6.71M | 3.50M | 108.81% |
| Dec 31, 2018 | 3.21M | 3.03M | 1,600.53% |
| Dec 31, 2017 | 189.00K | -1.44M | -88.39% |
| Dec 31, 2016 | 1.63M | 1.48M | 964.05% |
| Dec 31, 2015 | 153.00K | -388.16K | -71.73% |
| Dec 31, 2014 | 541.16K | -693.86K | -56.18% |
| Dec 31, 2013 | 1.24M | 230.96K | 23.00% |
| Dec 31, 2012 | 1.00M | -813.40K | -44.75% |
| Dec 31, 2011 | 1.82M | 107.76K | 6.30% |
| Dec 31, 2010 | 1.71M | 23.87K | 1.42% |
| Dec 31, 2009 | 1.69M | -666.11K | -28.32% |
| Aug 31, 2007 | 2.35M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| C-Rad AB | 444.40M |
| Mentice AB | 303.13M |
| Devyser Diagnostics AB | 250.30M |
| Bactiguard Holding AB | 206.94M |
| Sedana Medical AB | 195.46M |
| OssDsign AB | 163.80M |
| BrainCool AB | 46.49M |
| Ortoma AB | 33.90M |
Senzime AB News
- 4 weeks ago - Senzime Awarded Exclusive 5-Year National Supply Contract with U.S. Veterans Affairs Through Its Partner TrillaMed - Accesswire
- 7 weeks ago - Interim Report Q2 2026: Strong Sensor Sales and Improved Margins, Despite Continued U.S. Monitor Market Headwinds - Accesswire
- 7 weeks ago - Senzime AB Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Senzime AB Slides: Q2 2026 - Filings
- 7 weeks ago - Senzime and Philips Medical Systems Enter Development and Commercialization Partnership - Accesswire
- 7 weeks ago - Invitation to Presentations of Senzime's Second Quarter 2026 Report - Accesswire
- 2 months ago - Senzime's TetraGraph System Receives ANVISA Regulatory Approval in Brazil - Accesswire
- 3 months ago - Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026 - Accesswire